Clinical Trial Update: Study Evaluating Prevenar Immunogenicity in High Risk Children [Phase 4]

View source ↗

Summary

Phase 4 study evaluating immunogenicity of Prevenar in high-risk children has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevenar (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal Conjugate Vaccine | Phase 4 | Status: COMPLETED